PACS Group (PACS) Is Up 22.1% After Q1 Beat, Guidance Hike and Buyback Launch

PACS Group, Inc. recently reported that first-quarter 2026 revenue rose to US$1,420.49 million with net income of US$80.7 million, while reaffirming full-year 2026 revenue guidance of US$5.65–US$5.75 billion and authorizing a US$250 million share repurchase program. Alongside acquiring Ridgeway Senior Living in Anchorage and planning a new 150-bed skilled nursing facility, the company lifted its 2026 adjusted EBITDA outlook as portfolio maturation, improved occupancy, and contract renegotiations bolstered operating performance despite ongoing regulatory and internal control challenges. We’ll now examine how PACS Group’s stronger-than-expected Q1 earnings and higher adjusted EBITDA guidance shape its broader investment narrative.

Uncover the next big thing with 28 elite penny stocks that balance risk and reward.

PACS Group Investment Narrative Recap

PACS Group’s story still comes down to whether you believe it can keep improving occupancy and margins across its expanded facility base while staying on the right side of regulators and payors. The stronger than expected Q1 2026 earnings and higher adjusted EBITDA outlook reinforce the near term earnings catalyst, but do not remove the biggest risk around ongoing government investigations and internal control weaknesses, which could introduce financial and reputational pressure.

Among the recent announcements, the US$250 million share repurchase authorization stands out alongside the raised adjusted EBITDA guidance, as both tie directly to the near term earnings and cash generation narrative that many shareholders are watching most closely.

Yet against this stronger quarter, investors still need to consider the open DOJ and SEC matters that could...

Read the full narrative on PACS Group (it's free!)

PACS Group's narrative projects $6.6 billion revenue and $718.5 million earnings by 2028. This requires 8.6% yearly revenue growth and a $549.5 million earnings increase from $169.0 million today.

Uncover how PACS Group's forecasts yield a $35.00 fair value, a 15% downside to its current price.

Exploring Other PerspectivesPACS 1-Year Stock Price Chart

Three members of the Simply Wall St Community currently see PACS Group’s fair value between US$35 and about US$61, underscoring how far apart individual views can be. You might weigh those against the recent earnings beat and raised adjusted EBITDA guidance to judge how much execution risk around integration and reimbursement still matters for the company’s future performance.

Explore 3 other fair value estimates on PACS Group - why the stock might be worth as much as 49% more than the current price!

Story Continues

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

A great starting point for your PACS Group research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision. Our free PACS Group research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate PACS Group's overall financial health at a glance.

Searching For A Fresh Perspective?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality. Find 47 companies with promising cash flow potential yet trading below their fair value. The future of work is here. Discover the 30 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include PACS.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments